Residency · Residency · Child Adolescent Psychiatry

Non-Stimulant and Emerging Treatments for ADHD

Overview

Non-stimulant medications serve as second-line agents for ADHD, used when stimulants are ineffective, poorly tolerated, contraindicated, or when diversion risk is a concern. Their effect sizes are generally smaller than those of stimulants (0.3-0.7 versus 0.8-1.0), which is why they remain second-line. Four non-stimulant medications currently have FDA approval for ADHD: atomoxetine, guanfacine extended-release, clonidine extended-release, and viloxazine extended-release. A key advantage shared by all of these agents is the absence of abuse potential — none are scheduled substances.

Atomoxetine (Strattera)

Mechanism

Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI). By blocking the norepinephrine transporter, it increases both norepinephrine and dopamine concentrations in the prefrontal cortex — dopamine is also transported by the norepinephrine transporter in this region — without significantly increasing dopamine in the striatum or nucleus accumbens. This pharmacological profile explains why atomoxetine has no abuse potential: the dopamine increase occurs where it helps cognition (the PFC) but not where it produces euphoria (the reward circuitry).

Efficacy

Atomoxetine produces an effect size of approximately 0.6-0.7 for ADHD symptom reduction. Unlike stimulants, which work within hours, the full therapeutic effect of atomoxetine takes 4 to 6 weeks to manifest, a delay that must be clearly communicated to families to prevent premature discontinuation. It benefits both inattentive and hyperactive-impulsive symptoms and may be particularly useful when ADHD is comorbid with anxiety, as there is evidence of anxiolytic benefit. It provides continuous 24-hour coverage without the rebound effects seen with stimulants.

Dosing

Treatment begins at 0.5 mg/kg/day for 1-2 weeks, then increases to a target of 1.2 mg/kg/day (maximum 1.4 mg/kg/day or 100 mg/day). It can be given once daily — either morning or evening — or split into twice-daily dosing. Approximately 7% of Caucasian individuals are CYP2D6 poor metabolizers, who will achieve higher plasma levels and may require lower doses.

Side Effects

The most common side effects are gastrointestinal — nausea, decreased appetite, and abdominal pain — which are often transient. Fatigue and somnolence may occur, particularly with evening dosing. The FDA has placed a black box warning on atomoxetine for rare suicidal ideation, analogous to the warning on antidepressants, requiring informed consent and monitoring during early treatment. Hepatotoxicity is extremely rare but potentially severe; clinicians should monitor for jaundice and dark urine. Small increases in heart rate and blood pressure occur but are less pronounced than with stimulants. Urinary hesitancy may occur in some patients. Growth effects are modest but less than those seen with stimulants.

Clinical Considerations

Atomoxetine is a particularly good option for patients with comorbid anxiety, tic disorders, or substance use risk. The black box warning for suicidal ideation requires informed consent and close monitoring, especially during the early weeks. Families must understand the delayed onset of action to avoid giving up too soon. Atomoxetine can be combined with stimulants in partial responders, an off-label but common clinical practice.

Alpha-2 Adrenergic Agonists

Guanfacine Extended-Release (Intuniv)

Mechanism

Guanfacine is a selective alpha-2A adrenergic agonist that enhances prefrontal cortical function by strengthening network connectivity through post-synaptic alpha-2A receptor stimulation. By reducing "noise" in prefrontal circuits, it improves attention and impulse control. It also reduces sympathetic tone, which accounts for its cardiovascular effects and its ability to address hyperarousal symptoms.

Efficacy

Guanfacine ER produces an effect size of approximately 0.5-0.6 for ADHD symptoms and is particularly effective for hyperactivity-impulsivity and emotional dysregulation. It carries FDA approval both as monotherapy and as adjunctive therapy with stimulants. Beyond ADHD symptoms, it reduces tics (making it useful in comorbid Tourette syndrome), may improve oppositional behavior, and helps with insomnia.

Dosing

Treatment starts at 1 mg daily, titrating by 1 mg per week to a target of 0.05-0.12 mg/kg/day. Maximum doses are 4 mg/day for ages 6-12 and 7 mg/day for ages 13-17. Bedtime dosing is recommended initially to minimize sedation, though morning dosing becomes feasible once the patient has adjusted. Crucially, guanfacine must be tapered gradually rather than stopped abruptly, as sudden discontinuation can cause rebound hypertension.

Side Effects

Somnolence and sedation are the most common and often dose-limiting side effects, though they tend to improve over 2-3 weeks. Hypotension and bradycardia require vital sign monitoring. Dizziness, fatigue, and dry mouth may also occur. The risk of rebound hypertension and tachycardia with abrupt discontinuation is clinically important and must be communicated to families.

Clonidine Extended-Release (Kapvay)

Mechanism

Clonidine is a non-selective alpha-2 adrenergic agonist, binding alpha-2A, 2B, and 2C receptor subtypes. Its less selective pharmacology compared to guanfacine may explain its greater sedative effect and relatively less cognitive benefit.

Efficacy

Clonidine ER produces a smaller effect size of approximately 0.4-0.5. It has FDA approval as both monotherapy and adjunctive therapy for ADHD. Because it is more sedating than guanfacine, it is often used specifically when ADHD-related insomnia is a prominent concern. It also helps with tics, hyperarousal, and aggression.

Dosing

Treatment begins at 0.1 mg at bedtime, titrating by 0.1 mg per week to a target of 0.1-0.4 mg/day divided into twice-daily dosing. Like guanfacine, it must be tapered gradually to avoid rebound hypertension.

Side Effects

Clonidine produces more sedation than guanfacine, along with hypotension, bradycardia, dry mouth, and constipation. Rebound hypertension with abrupt discontinuation is the most important safety concern.

Guanfacine vs. Clonidine: Clinical Decision-Making

Guanfacine is generally preferred over clonidine for ADHD because of its greater alpha-2A selectivity and less pronounced sedation. Clonidine may be preferred when sedation is actually desirable, such as in children with prominent insomnia or hyperarousal. Both medications are valuable adjuncts to stimulants when stimulant monotherapy provides only a partial response, and both are useful for the ADHD-plus-Tourette syndrome subgroup.

Viloxazine Extended-Release (Qelbree)

Mechanism

Viloxazine is a norepinephrine reuptake inhibitor with additional serotonergic modulating activity, including 5-HT2B agonism, 5-HT2C antagonism, and 5-HT7 antagonism. Originally marketed as an antidepressant in Europe from the 1970s through the 2000s, it has been repurposed for ADHD. It increases both norepinephrine and serotonin in the prefrontal cortex.

Efficacy

Viloxazine ER produces an effect size of approximately 0.4-0.6. It received FDA approval for ADHD in children ages 6-11 and adolescents 12-17 in 2021, and for adults in 2022. Notably, it works within 1-2 weeks — faster than atomoxetine. Its serotonergic activity may offer particular benefit when ADHD co-occurs with anxiety or emotional dysregulation.

Dosing

For children ages 6-11, treatment starts at 100 mg daily with titration to 200-400 mg/day. For adolescents ages 12-17, the starting dose is 200 mg daily, titrating to 200-400 mg/day. It is given once daily in the morning.

Side Effects

Common side effects include somnolence, decreased appetite, nausea, headache, and insomnia. Like atomoxetine, it carries an FDA boxed warning for suicidal thoughts and behaviors. It can increase blood pressure, requiring vital sign monitoring. An important drug interaction involves CYP1A2 inhibition, requiring caution with caffeine, theophylline, and certain other medications.

When to Choose Non-Stimulant Medications

Primary Indications

Non-stimulants are appropriate when there has been an inadequate response to or intolerable side effects from both stimulant classes; when the child has a comorbid tic disorder or Tourette syndrome (alpha-2 agonists are preferred here); when comorbid anxiety is prominent (atomoxetine or viloxazine may address both conditions); when there is active substance use disorder or high diversion risk; when the family prefers to avoid controlled substances; when there are cardiovascular contraindications to stimulants (though non-stimulants also have cardiac effects requiring monitoring); or when 24-hour symptom coverage without rebound is needed.

Combination Strategies

Combining a stimulant with guanfacine ER is an FDA-approved adjunctive strategy that addresses residual hyperactivity, emotional dysregulation, or insomnia. Combining a stimulant with atomoxetine is done off-label and may augment stimulant response, though evidence is limited. Multiple alpha-2 agonists should not be combined, and alpha-2 agonists should be used cautiously with other hypotensive agents, with appropriate blood pressure monitoring.

Emerging and Investigational Treatments

Several novel approaches are in various stages of development. Centanafadine is a triple reuptake inhibitor (norepinephrine, dopamine, and serotonin) that has completed Phase III trials. Mazindol, a dopamine/norepinephrine reuptake inhibitor, is being studied in a controlled-release formulation. EndeavorRx is an FDA-cleared prescription video game designed as a digital therapeutic for ADHD in children, though its effect sizes are modest. Transcranial direct current stimulation (tDCS) targeting the prefrontal cortex has early evidence but is not yet established. Neurofeedback, which involves EEG-based training, has mixed evidence and is not recommended as monotherapy. Computerized cognitive training programs targeting working memory have shown limited transfer to real-world functioning.

<image>A comparison table of non-stimulant medications for ADHD including atomoxetine, guanfacine ER, clonidine ER, and viloxazine ER. Columns: drug name, mechanism, FDA-approved ages, effect size, time to full effect, typical dose range, key side effects, special advantages, and warnings. Use color coding to group medications by class (NRI, alpha-2 agonist, NRI/serotonergic).</image>

<image>A clinical decision algorithm for selecting non-stimulant ADHD medications. Start with "Stimulants inadequate or contraindicated." Branch by primary clinical concern: if comorbid tics, guide to alpha-2 agonists; if comorbid anxiety, guide to atomoxetine or viloxazine; if diversion/abuse risk, guide to any non-stimulant; if insomnia is prominent, guide to guanfacine or clonidine (bedtime dosing). Show second-line options and combination strategies.</image>

<image>A bar graph comparing effect sizes of ADHD medications: methylphenidate (~0.9), amphetamine (~1.0), atomoxetine (~0.6), guanfacine ER (~0.5), clonidine ER (~0.4), and viloxazine ER (~0.5). Include error bars and a note explaining that effect sizes are approximate and drawn from different meta-analyses with varying methodologies.</image>

Clinical Pearls

Non-stimulants are second-line for a reason — their effect sizes are consistently smaller than those of stimulants — but they are valuable when stimulants fail or are contraindicated. Atomoxetine takes 4-6 weeks for full effect, and premature discontinuation due to this delay is common and should be anticipated in counseling. Guanfacine ER is generally preferred over clonidine ER for ADHD because of its greater alpha-2A selectivity and reduced sedation. Both atomoxetine and viloxazine carry FDA black box warnings for suicidal ideation, requiring careful monitoring during initiation. Alpha-2 agonists must be tapered and never stopped abruptly due to the risk of rebound hypertension. Non-stimulants have no abuse potential, making them attractive options for adolescents with concurrent substance use concerns. Combining a stimulant with guanfacine ER is an FDA-approved strategy for patients who show only a partial response to stimulant monotherapy. Viloxazine is the newest FDA-approved option and may be particularly useful for ADHD with comorbid anxiety given its serotonergic activity.

References

• Sallee, F.R. et al. (2009). Guanfacine extended release in children and adolescents with ADHD. Pediatrics, 123(1), e13-e19.
• Kratochvil, C.J. et al. (2002). Atomoxetine and methylphenidate treatment in children with ADHD. JAACAP, 41(7), 776-784.
• Nasser, A. et al. (2021). Viloxazine extended-release capsules for ADHD in children and adolescents: Phase III trial results. JAACAP, 60(10), S178-S179.
• Cortese, S. et al. (2018). Comparative efficacy and tolerability of medications for ADHD. Lancet Psychiatry, 5(9), 727-738.
• Faraone, S.V. et al. (2021). ADHD International Consensus Statement. Neuroscience & Biobehavioral Reviews, 128, 789-818.
• Connor, D.F. et al. (2010). Alpha-2 adrenergic agonists for ADHD. Expert Opinion on Pharmacotherapy, 11(2), 269-283.

Read this lecture as Markdown